Water-insoluble medicine

Abstract

A water-insoluble medicine in the form of particulates, having an average particle diameter of 50 to 200 nm; and a particulate complex of the water-insoluble medicine and a polymer electrolyte, having an average particle diameter of 50 to 250 nm.

1 . A water-insoluble medicine in the form of particulates, having an average particle diameter of 50 to 200 nm.  
     
     
         2 . The water-insoluble medicine according to  claim 1 , which has at least one multiple bond in the structure.  
     
     
         3 . The water-insoluble medicine according to  claim 1  or  2 , which is an anti-cancer drug.  
     
     
         4 . The water-insoluble medicine according to  claim 3 , wherein said anti-cancer drug is a camptothecin derivative.  
     
     
         5 . The water-insoluble medicine according to  claim 3 , wherein said anti-cancer drug is an ellipticine derivative.  
     
     
         6 . The water-insoluble medicine according to  claim 3 , wherein said anti-cancer drug is a podophyllotoxin derivative.  
     
     
         7 . A particulate complex of the water-insoluble medicine of any one of  claims 1  to  6  with a polymer electrolyte, having an average particle diameter of 50 to 250 mm.  
     
     
         8 . The particulate complex according to  claim 7 , wherein said polymer electrolyte is at least one member selected from the group consisting of: biocompatible polymers including protamine, gelatin A, collagen, albumin, casein, chitosan, poly-(L)-lysine, carboxymethyl cellulose, alginate, heparin, hyaluronic acid, chondroitin sulfate, gelatin B, carageenan, dextran sulfate, and poly-(L)-glutamic acid; biopolymers including biodegradable polymers, DNA, RNA, enzymes and antibodies; synthesized polymers including polymethacrylic acid, polydiaryldimethylammonium; and polymers in which such synthesized polymers are crosslinked with an appropriate linker.